Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema.
We report the case of a patient with scleromyxedema with abnormal monoclonal gamma globulin of the kappa type who was treated with melphalan (Alkeran), an alkylating agent. After nine and one-half years of therapy, the patient showed myelomonocytic leukemia. The risk of secondary malignancies must be considered when weighting the benefits and risks of melphalan treatment.
Helm
F
F
Helm
T N
TN
D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced*; D008297:Male; D008558:Melphalan / Q000009:adverse effects*; D010265:Paraproteinemias / Q000097:blood / Q000150:complications*; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*
D008558:Melphalan